Interleukin-37 as a biomarker of mortality risk in patients with sepsis
- 2 February 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Infection
- Vol. 82 (3), 346-354
- https://doi.org/10.1016/j.jinf.2021.01.019
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 48 references indexed in Scilit:
- Interleukin-37 is elevated in subjects with atopic dermatitisJournal of Dermatological Science, 2013
- New Insights in the Immunobiology of IL-1 Family MembersFrontiers in Immunology, 2013
- Glucocorticoid Regulates Interleukin-37 in Systemic Lupus ErythematosusJournal of Clinical Immunology, 2012
- IL-37 is a fundamental inhibitor of innate immunityNature Immunology, 2010
- Procalcitonin assay in systemic inflammation, infection, and sepsis: Clinical utility and limitationsCritical Care Medicine, 2008
- Cytokine profiles as markers of disease severity in sepsis: a multiplex analysisCritical Care, 2007
- Genomic Organization of the Interleukin-1 LocusGenomics, 2002
- Diagnostic Value of Procalcitonin, Interleukin-6, and Interleukin-8 in Critically Ill Patients Admitted with Suspected SepsisAmerican Journal of Respiratory and Critical Care Medicine, 2001
- The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre studyIntensive Care Medicine, 1999
- The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome.The Journal of Experimental Medicine, 1989